Symbols / XENE
XENE Chart
About
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.46B |
| Enterprise Value | 3.01B | Income | -306.33M | Sales | 7.50M |
| Book/sh | 7.25 | Cash/sh | 5.98 | Dividend Yield | — |
| Payout | 0.00% | Employees | 316 | IPO | — |
| P/E | — | Forward P/E | -9.60 | PEG | — |
| P/S | 461.49 | P/B | 6.17 | P/C | — |
| EV/EBITDA | -8.89 | EV/Sales | 400.96 | Quick Ratio | 12.08 |
| Current Ratio | 12.53 | Debt/Eq | 1.49 | LT Debt/Eq | — |
| EPS (ttm) | -3.89 | EPS next Y | -4.66 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -29.50% |
| ROE | -45.14% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -45.44% | Profit Margin | 0.00% | Shs Outstand | 77.28M |
| Shs Float | 71.77M | Short Float | 7.99% | Short Ratio | 5.32 |
| Short Interest | — | 52W High | 46.60 | 52W Low | 26.74 |
| Beta | 0.93 | Avg Volume | 872.56K | Volume | 931.58K |
| Target Price | $56.22 | Recom | Strong_buy | Prev Close | $42.72 |
| Price | $44.79 | Change | 4.85% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$56.22
Mean price target
2. Current target
$44.79
Latest analyst target
3. DCF / Fair value
$-37.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$44.79
Low
$44.00
High
$66.00
Mean
$56.22
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Wolfe Research | — → Outperform | $60 |
| 2026-01-09 | main | JP Morgan | Overweight → Overweight | $62 |
| 2025-12-11 | main | Wells Fargo | Overweight → Overweight | $48 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $60 |
| 2025-11-04 | main | RBC Capital | Outperform → Outperform | $58 |
| 2025-11-04 | main | Wells Fargo | Overweight → Overweight | $44 |
| 2025-11-04 | reit | Needham | Buy → Buy | $55 |
| 2025-10-07 | main | Chardan Capital | Buy → Buy | $55 |
| 2025-09-02 | reit | RBC Capital | Outperform → Outperform | $55 |
| 2025-08-12 | main | Chardan Capital | Buy → Buy | $55 |
| 2025-08-12 | main | RBC Capital | Outperform → Outperform | $55 |
| 2025-08-12 | main | Wedbush | Outperform → Outperform | $43 |
| 2025-06-13 | main | RBC Capital | Outperform → Outperform | $57 |
| 2025-05-14 | init | Evercore ISI Group | — → Outperform | $55 |
| 2025-05-13 | main | Wells Fargo | Overweight → Overweight | $47 |
| 2025-05-13 | main | RBC Capital | Outperform → Outperform | $55 |
| 2025-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $53 |
| 2025-05-13 | main | Needham | Buy → Buy | $55 |
| 2025-05-13 | main | Chardan Capital | Buy → Buy | $55 |
| 2025-05-07 | init | Chardan Capital | — → Buy | $55 |
- Xenon Pharmaceuticals Stock Scores RS Rating Upgrade - Investor's Business Daily ue, 24 Feb 2026 18
- A Look At Xenon Pharmaceuticals (XENE) Valuation After Wolfe Research’s New Favorable Coverage - Yahoo Finance ue, 24 Feb 2026 19
- Wolfe Research Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform Recommendation - Nasdaq ue, 24 Feb 2026 13
- Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail Wed, 25 Feb 2026 02
- XENE: Xenon Pharmaceuticals Coverage Initiated by Wolfe Research - GuruFocus ue, 24 Feb 2026 13
- Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data - The Motley Fool hu, 19 Feb 2026 22
- Understanding Momentum Shifts in (XENE) - Stock Traders Daily ue, 17 Feb 2026 06
- Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating - Investing.com Australia ue, 24 Feb 2026 16
- Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha hu, 18 Dec 2025 08
- Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - TechStock² Mon, 05 Jan 2026 08
- A Look At Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Swings - simplywall.st Sun, 25 Jan 2026 08
- Is Xenon Pharmaceuticals (NASDAQ:XENE) Rising In The Nasdaq Index - Kalkine Media Fri, 20 Feb 2026 08
- Xenon Pharmaceuticals Awards $1.5M in Stock Options to 7 New Hires Under Nasdaq Rule - Stock Titan Fri, 30 May 2025 07
- Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Globe and Mail Mon, 23 Feb 2026 19
- Avoiding Lag: Real-Time Signals in (XENE) Movement - Stock Traders Daily Fri, 06 Feb 2026 05
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40000 | 1777093 | — | Sale at price 44.40 - 44.93 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 40000 | 299600 | — | Conversion of Exercise of derivative security at price 7.49 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 25205 | 1142513 | — | Sale at price 45.03 - 46.32 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2025-12-08 00:00:00 | D |
| 3 | 97 | 4366 | — | Sale at price 45.01 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2025-11-28 00:00:00 | D |
| 4 | 25000 | 1004000 | — | Sale at price 40.16 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2025-10-01 00:00:00 | D |
| 5 | 25000 | 192250 | — | Conversion of Exercise of derivative security at price 7.69 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2025-10-01 00:00:00 | D |
| 6 | 3 | 91 | — | Sale at price 30.48 per share. | GANNON STEVEN | Director | — | 2025-06-05 00:00:00 | D |
| 7 | 5144 | 64660 | — | Conversion of Exercise of derivative security at price 12.57 per share. | GANNON STEVEN | Director | — | 2025-05-14 00:00:00 | D |
| 8 | 55000 | 2213997 | — | Sale at price 40.08 - 41.07 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2025-01-27 00:00:00 | D |
| 9 | 55000 | 976800 | — | Conversion of Exercise of derivative security at price 17.76 per share. | MORTIMER IAN C | Chief Executive Officer | — | 2025-01-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -18.09K | 7.50K | -1.26M | -27.46 |
| TaxRateForCalcs | 0.02 | 0.00 | 0.26 | 0.00 |
| NormalizedEBITDA | -275.67M | -215.74M | -122.91M | -77.73M |
| TotalUnusualItems | -1.06M | 3.75M | -4.83M | -361.00K |
| TotalUnusualItemsExcludingGoodwill | -1.06M | 3.75M | -4.83M | -361.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -234.33M | -182.39M | -125.37M | -78.88M |
| ReconciledDepreciation | 2.56M | 2.06M | 1.41M | 906.00K |
| EBITDA | -276.74M | -211.99M | -127.74M | -78.09M |
| EBIT | -279.30M | -214.05M | -129.14M | -78.99M |
| NetInterestIncome | 41.94M | 27.62M | 8.71M | 466.00K |
| InterestExpense | 0.00 | 0.00 | ||
| InterestIncome | 41.94M | 27.62M | 8.71M | 466.00K |
| NormalizedIncome | -233.28M | -186.13M | -121.81M | -78.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -234.33M | -182.39M | -125.37M | -78.88M |
| TotalExpenses | 279.30M | 214.05M | 138.58M | 97.43M |
| TotalOperatingIncomeAsReported | -279.30M | -214.05M | -129.14M | -78.99M |
| DilutedAverageShares | 77.89M | 66.89M | 60.54M | 43.63M |
| BasicAverageShares | 77.89M | 66.89M | 60.54M | 43.63M |
| DilutedEPS | -3.01 | -2.73 | -2.06 | -1.77 |
| BasicEPS | -3.01 | -2.73 | -2.06 | -1.77 |
| DilutedNIAvailtoComStockholders | -234.33M | -182.39M | -124.94M | -77.09M |
| NetIncomeCommonStockholders | -234.33M | -182.39M | -124.94M | -77.09M |
| PreferredStockDividends | -437.00K | -1.79M | ||
| NetIncome | -234.33M | -182.39M | -125.37M | -78.88M |
| NetIncomeIncludingNoncontrollingInterests | -234.33M | -182.39M | -125.37M | -78.88M |
| NetIncomeContinuousOperations | -234.33M | -182.39M | -125.37M | -78.88M |
| TaxProvision | -4.09M | -292.00K | 118.00K | -6.00K |
| PretaxIncome | -238.42M | -182.69M | -125.25M | -78.89M |
| OtherIncomeExpense | -1.06M | 3.75M | -4.83M | -361.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | -1.06M | 3.75M | -4.83M | -361.00K |
| NetNonOperatingInterestIncomeExpense | 41.94M | 27.62M | 8.71M | 466.00K |
| InterestExpenseNonOperating | 0.00 | 0.00 | ||
| InterestIncomeNonOperating | 41.94M | 27.62M | 8.71M | 466.00K |
| OperatingIncome | -279.30M | -214.05M | -129.14M | -78.99M |
| OperatingExpense | 279.30M | 214.05M | 138.58M | 97.43M |
| ResearchAndDevelopment | 210.39M | 167.51M | 105.77M | 75.46M |
| SellingGeneralAndAdministration | 68.90M | 46.54M | 32.81M | 21.97M |
| GeneralAndAdministrativeExpense | 68.90M | 46.54M | 32.81M | 21.97M |
| OtherGandA | 68.90M | 46.54M | 32.81M | 21.97M |
| TotalRevenue | 0.00 | 0.00 | 9.43M | 18.44M |
| OperatingRevenue | 0.00 | 0.00 | 9.43M | 18.44M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 76.42M | 75.37M | 62.59M | 51.63M |
| ShareIssued | 76.42M | 75.37M | 62.59M | 51.63M |
| TotalDebt | 9.02M | 10.90M | 10.44M | 8.26M |
| TangibleBookValue | 754.90M | 927.92M | 721.50M | 542.30M |
| InvestedCapital | 754.90M | 927.92M | 721.50M | 542.30M |
| WorkingCapital | 599.67M | 617.69M | 577.60M | 544.70M |
| NetTangibleAssets | 754.90M | 927.92M | 721.50M | 550.03M |
| CapitalLeaseObligations | 9.02M | 10.90M | 10.44M | 8.26M |
| CommonStockEquity | 754.90M | 927.92M | 721.50M | 542.30M |
| PreferredStockEquity | 7.73M | |||
| TotalCapitalization | 754.90M | 927.92M | 721.50M | 550.03M |
| TotalEquityGrossMinorityInterest | 754.90M | 927.92M | 721.50M | 550.03M |
| StockholdersEquity | 754.90M | 927.92M | 721.50M | 550.03M |
| GainsLossesNotAffectingRetainedEarnings | -1.61M | -77.00K | -3.00M | -990.00K |
| OtherEquityAdjustments | -1.61M | -77.00K | -3.00M | -990.00K |
| RetainedEarnings | -899.47M | -665.14M | -482.75M | -357.37M |
| AdditionalPaidInCapital | 199.15M | 156.76M | 142.11M | 117.50M |
| CapitalStock | 1.46B | 1.44B | 1.07B | 790.90M |
| CommonStock | 1.46B | 1.44B | 1.07B | 783.17M |
| PreferredStock | 0.00 | 7.73M | ||
| TotalLiabilitiesNetMinorityInterest | 43.24M | 36.88M | 32.65M | 21.97M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.65M | 9.60M | 9.95M | 7.65M |
| LongTermDebtAndCapitalLeaseObligation | 7.65M | 9.60M | 9.95M | 7.65M |
| LongTermCapitalLeaseObligation | 7.65M | 9.60M | 9.95M | 7.65M |
| CurrentLiabilities | 35.59M | 27.27M | 22.70M | 14.32M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 1.37M | 1.30M | 488.00K | 605.00K |
| CurrentCapitalLeaseObligation | 1.37M | 1.30M | 488.00K | 605.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.93M | 7.42M | 5.82M | 5.94M |
| PayablesAndAccruedExpenses | 24.29M | 18.55M | 16.39M | 7.78M |
| CurrentAccruedExpenses | 13.54M | 9.60M | 7.90M | 3.95M |
| Payables | 10.76M | 8.95M | 8.49M | 3.82M |
| TotalTaxPayable | 5.69M | 347.00K | ||
| AccountsPayable | 5.07M | 8.60M | 8.49M | 3.82M |
| TotalAssets | 798.14M | 964.80M | 754.15M | 572.01M |
| TotalNonCurrentAssets | 162.88M | 319.84M | 153.85M | 12.99M |
| NonCurrentPrepaidAssets | 7.50M | 7.40M | 7.75M | 0.00 |
| NonCurrentDeferredAssets | 9.67M | 802.00K | 509.00K | 465.00K |
| NonCurrentDeferredTaxesAssets | 9.67M | 802.00K | 509.00K | 465.00K |
| InvestmentsAndAdvances | 127.50M | 292.79M | 128.68M | 0.00 |
| InvestmentinFinancialAssets | 127.50M | 292.79M | 128.68M | 0.00 |
| AvailableForSaleSecurities | 127.50M | 292.79M | 128.68M | |
| NetPPE | 18.22M | 18.85M | 16.91M | 12.52M |
| AccumulatedDepreciation | -13.46M | -11.25M | -8.71M | -13.35M |
| GrossPPE | 31.68M | 30.10M | 25.61M | 25.87M |
| Leases | 9.36M | 9.02M | 4.20M | 7.02M |
| OtherProperties | 11.63M | 9.11M | 8.92M | 8.42M |
| MachineryFurnitureEquipment | 2.75M | 2.77M | 2.08M | 2.37M |
| BuildingsAndImprovements | 7.94M | 9.19M | 10.41M | 8.06M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 635.26M | 644.96M | 600.30M | 559.02M |
| OtherCurrentAssets | 6.89M | 6.01M | 7.22M | 4.48M |
| PrepaidAssets | 4.48M | |||
| Receivables | 1.47M | 874.00K | 986.00K | 2.77M |
| AccountsReceivable | 1.47M | 874.00K | 986.00K | 2.77M |
| CashCashEquivalentsAndShortTermInvestments | 626.90M | 638.08M | 592.09M | 551.77M |
| OtherShortTermInvestments | 484.19M | 489.44M | 534.85M | 376.09M |
| CashAndCashEquivalents | 142.71M | 148.64M | 57.24M | 175.69M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -184.46M | -156.73M | -103.92M | -71.55M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 12.08M | 353.49M | 277.77M | 447.28M |
| CapitalExpenditure | -3.08M | -5.62M | -2.89M | -2.05M |
| InterestPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 142.71M | 148.64M | 57.24M | 175.69M |
| BeginningCashPosition | 148.64M | 57.24M | 175.69M | 45.01M |
| EffectOfExchangeRateChanges | -1.67M | 376.00K | -2.48M | -592.00K |
| ChangesInCash | -4.26M | 91.03M | -115.96M | 131.27M |
| FinancingCashFlow | 12.13M | 353.52M | 278.47M | 447.54M |
| CashFlowFromContinuingFinancingActivities | 12.13M | 353.52M | 278.47M | 447.54M |
| ProceedsFromStockOptionExercised | 47.00K | 35.00K | 705.00K | 260.00K |
| NetCommonStockIssuance | 12.08M | 353.49M | 277.77M | 447.28M |
| CommonStockIssuance | 12.08M | 353.49M | 277.77M | 447.28M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| InvestingCashFlow | 165.00M | -111.39M | -293.40M | -246.77M |
| CashFlowFromContinuingInvestingActivities | 165.00M | -111.39M | -293.40M | -246.77M |
| NetInvestmentPurchaseAndSale | 168.07M | -105.77M | -290.51M | -244.72M |
| SaleOfInvestment | 700.34M | 688.14M | 260.63M | 144.75M |
| PurchaseOfInvestment | -532.27M | -793.91M | -551.14M | -389.47M |
| NetPPEPurchaseAndSale | -3.08M | -5.62M | -2.89M | -2.05M |
| PurchaseOfPPE | -3.08M | -5.62M | -2.89M | -2.05M |
| OperatingCashFlow | -181.39M | -151.11M | -101.03M | -69.50M |
| CashFlowFromContinuingOperatingActivities | -181.39M | -151.11M | -101.03M | -69.50M |
| ChangeInWorkingCapital | 5.71M | 5.90M | -1.28M | -2.65M |
| ChangeInOtherWorkingCapital | -3.64M | |||
| ChangeInOtherCurrentLiabilities | -1.22M | 267.00K | -600.00K | |
| ChangeInPayablesAndAccruedExpense | 8.53M | 3.93M | 8.06M | 2.97M |
| ChangeInPrepaidAssets | -984.00K | 1.57M | -10.49M | -1.52M |
| ChangeInReceivables | -614.00K | 130.00K | 1.76M | -459.00K |
| ChangesInAccountReceivables | -614.00K | 130.00K | 1.76M | -459.00K |
| OtherNonCashItems | 1.25M | 1.21M | 819.00K | |
| StockBasedCompensation | 50.72M | 32.37M | 20.38M | 10.02M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -3.55M | 2.93M | 719.00K |
| AmortizationOfSecurities | 816.00K | -5.79M | -2.60M | |
| DeferredTax | -8.86M | -292.00K | -44.00K | 58.00K |
| DeferredIncomeTax | -8.86M | -292.00K | -44.00K | 58.00K |
| DepreciationAmortizationDepletion | 2.56M | 2.06M | 1.41M | 906.00K |
| DepreciationAndAmortization | 2.56M | 2.06M | 1.41M | 906.00K |
| Depreciation | 2.56M | 2.06M | 1.41M | 906.00K |
| OperatingGainsLosses | 745.00K | -640.00K | 2.73M | 327.00K |
| GainLossOnInvestmentSecurities | 2.93M | 719.00K | ||
| NetForeignCurrencyExchangeGainLoss | 745.00K | -640.00K | 2.73M | 327.00K |
| NetIncomeFromContinuingOperations | -234.33M | -182.39M | -125.37M | -78.88M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XENE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|